N,N-Diaethyl-1-methyl-p-phenylendiamin | 84995-57-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-Diaethyl-1-methyl-p-phenylendiamin
• 英文别名: N,N-diethyl-N'-methyl-p-phenylenediamine；N1,N1-diethyl-N4-methylbenzene-1,4-diamine；4-N,4-N-diethyl-1-N-methylbenzene-1,4-diamine
• CAS: 84995-57-3
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.277
• InChiKey: FAQOSJSLHPNZGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  硫光气 、 N,N-Diaethyl-1-methyl-p-phenylendiamin 、 potassium carbonate 以 氯仿 为溶剂， 生成 1,3-dimethyl-1,3-bis-(4-diethylaminophenyl)-thiourea
  参考文献：
  名称：

  Non-staining and slightly-staining antiozonants

  摘要：

  披露了一种化合物，其结构式中具有三价基团：##STR1##，当以抗臭氧剂有效水平添加到橡胶组合物中时表现出抗臭氧活性，并且当与橡胶组合物中的传统抗臭氧剂一起使用时表现出协同抗臭氧活性。还披露了可以用作抗臭氧剂的新化合物。

  公开号：

  US05019611A1

文献信息

• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Hummersone Marc Geoffrey

  公开号：US20080194546A1

  公开（公告）日：2008-08-14

  There is provided a compound of formula I: wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R 7 is selected from halo, OR O1 , SR S1 , NR N1 R N2 , NR N7a C(═O)R C1 , NR N7b SO 2 R S2a , an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 5-20 aryl group, where R O1 and R S1 are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N1 and R N2 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N1 and R N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R C1 is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 1-7 alkyl group or NR N8 R N9 , where R N8 and R N9 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N8 and R N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R S2a is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N7a and R N7b are selected from H and a C 1-4 alkyl group; R N3 and R N4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR O2 , SR S2b , NR N5 R N6 , an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, wherein R O2 and R S2b are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N5 and R N6 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, or R N5 and R N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino. R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一种化合物，其化学式为I：其中：X5、X6和X8中的一个或两个是N，其余为CH；R7选自卤素、ORO1、SRS1、NRN1RN2、NRN7aC（═O）RC1、NRN7bSO2RS2a、可选取代的C5-20杂环芳基基团或可选取代的C5-20芳基基团，其中RO1和RS1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN1和RN2独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN1和RN2与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RC1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团、可选取代的C1-7烷基基团或NRN8RN9，其中RN8和RN9独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN8和RN9与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RS2a选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN7a和RN7b选自H和C1-4烷基基团；RN3和RN4与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；R2选自H、卤素、ORO2、SRS2b、NRN5RN6、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，其中RO2和RS2b选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN5和RN6独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，或RN5和RN6与它们所连接的氮原子一起形成含有3至8个环原子的杂环环，或其药学上可接受的盐，但当R2为未取代的吗啡啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的吗啡啶基，R7为未取代的苯基，且X5为CH时，X6不是N且X8不是CH，或X6不是CH且X8不是N，当R2为未取代的哌啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的哌啶基，R7为未取代的苯基，且X5为CH时，X6不是CH且X不是N。还提供了制造化合物I的方法，以及将化合物I用作药物治疗癌症的用途。
• COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS
  申请人：Ren Pingda

  公开号：US20090312321A1

  公开（公告）日：2009-12-17

  Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDK1, CHK2, CK1, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphB1, FES, FGFR1, FGFR2, FGFR3, Flt1, Flt3, FMS, Fyn, GSK3β, IGF-1R, IKKα, IKKβ, IR, IRAK4, ITK, JAK2, JAK3, JNK1α1, JNK2α, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEK1, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, PDGFR, PDGFRα, PDK1, Pim-2, Plk3, PKA, PKBα, PKCα, PKCtheta, PKD2, c-Raf, RET, ROCK-I, ROCK-II, Ron, Ros, Rsk1, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70.

  本文介绍了化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与异常或非调节激酶活性相关的疾病或紊乱的方法，特别是涉及Abl、ALK、AMPK、AuroRA、Axl、Bcr-Abl、BIK、Bmx、BRK、BTK、c-Kit、CSK、cSrc、CDK1、CHK2、CK1、CK2、CaMKII、CaMKIV、DYRK2、EGFR、EphB1、FES、FGFR1、FGFR2、FGFR3、Flt1、Flt3、FMS、Fyn、GSK3β、IGF-1R、IKKα、IKKβ、IR、IRAK4、ITK、JAK2、JAK3、JNK1α1、JNK2α、KDR、Lck、LYN、MAPK1、MAPKAP-K2、MEK1、MET、MKK4、MKK6、MST2、NEK2、NLK、p70S6K、PAK2、PDGFR、PDGFRα、PDK1、Pim-2、Plk3、PKA、PKBα、PKCα、PKCtheta、PKD2、c-RAf、RET、ROCK-I、ROCK-II、Ron、Ros、Rsk1、SAPK2a、SAPK2b、SAPK3、SAPK4、SGK、SIK、Syk、Tie2、TrkB、WNK3和ZAP-70等激酶异常活性的疾病或紊乱。
• Process for preparing polyamides
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0248932A1

  公开（公告）日：1987-12-16

  A process for preparing a polyamide which comprises polycondensing a dicarboxylic acid and a diamine by using a combination of at least one phos­phine and at least one disulfide as the condensing agent.

  一种制备聚酰胺的工艺，包括使用至少一种膦和至少一种二硫化物的组合作为缩合剂，对二羧酸和二胺进行缩聚。
• Curable dielectric polyphenylene ether-polyepoxide compositions useful in printed circuit board production
  申请人：GENERAL ELECTRIC COMPANY

  公开号：EP0374514A2

  公开（公告）日：1990-06-27

  Curable compositions containing a polyphenylene ether and a polyepoxide composition containing brominated and non-brominated bisphenol polyglycidyl ethers, in combination with further components including specific catalysts and hardeners, may be used in the preparation of laminates useful as printed circuit boards and bonding sheets therefor and having excellent physical and electrical properties.

  含有聚苯醚的可固化组合物和含有溴化和非溴化双酚聚缩水甘油醚的聚环氧化物组合物，与包括特定催化剂和固化剂在内的其他成分一起，可用于制备可用作印刷电路板和粘合片的层压板，并具有优异的物理和电气性能。
• Pigment dispersions for color filters, fabrication process of color filters, and color filters
  申请人：DAINICHISEIKA COLOR & CHEMICALS MFG. CO. LTD.

  公开号：EP1024179A1

  公开（公告）日：2000-08-02

  Pigment dispersions for color filters are composed of pigments, dispersants, film-forming resins and liquid media. The dispersants comprises compounds represented by the following formula (I): wherein X and X' each independently represent H, OH, alkoxy, primary, secondary or tertiary amino, or acylamino; Y represents an anthraquinonylamino, phenylamino or phenoxy group having H, OH, alkoxy, primary, secondary or tertiary amino, or acylamino at the 4-position or 5-position; A and B each independently represent alkyl, cycloalkyl or aryl, and at least one of A and B has at least one substituent group containing a basic nitrogen atom; and Z represents H, CN, halogen, alkyl, alkoxy, NO2, benzoylamino or 3-benzoyl, and the 3-benzoyl group may be fused together with X to form an acridone ring. These pigment dispersions are useful for the production of color filters.

  滤色片用颜料分散体由颜料、分散剂、成膜树脂和液体介质组成。分散剂包括下式 (I) 所代表的化合物： 其中 X 和 X'各自独立地代表 H、OH、烷氧基、伯氨基、仲氨基或叔氨基或酰氨基；Y 代表在 4 位或 5 位上具有 H、OH、烷氧基、伯氨基、仲氨基或叔氨基或酰氨基的蒽醌基氨基、苯基氨基或苯氧基；A 和 B 各自独立地代表烷基、环烷基或芳基，且 A 和 B 中至少有一个取代基含有碱基氮原子；Z 代表 H、CN、卤素、烷基、烷氧基、NO2、苯甲酰氨基或 3-苯甲酰基，3-苯甲酰基可与 X 融合在一起形成吖啶酮环。这些颜料分散体可用于生产彩色滤光片。